
Immunovia AB ( ($SE:IMMNOV) ) just unveiled an announcement. Multiple U.S. pancreatic cancer patient advocacy groups, including PanCAN, FORCE, the John R. Lewis Legacy Institute and the National Pancreas Foundation,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| IMMVF | Immunovia AB | 0.00 | -0.00 | -73.68% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.00 | -73.68% |

Immunovia AB ( ($SE:IMMNOV) ) just unveiled an announcement. Multiple U.S. pancreatic cancer patient advocacy groups, including PanCAN, FORCE, the John R. Lewis Legacy Institute and the National Pancreas Foundation,

Immunovia AB (($SE:IMMNOV)) has held its Q3 earnings call. Read on for the main highlights of the call. Immunovia’s earnings call carried a mostly positive tone, driven by sharp revenue

Immunovia AB ( ($SE:IMMNOV) ) has shared an update. Immunovia, a medical diagnostics company developing blood-based tests for pancreatic cancer detection, has published a prospectus for a SEK 63.4 million

Immunovia AB ( ($SE:IMMNOV) ) has shared an update. Immunovia’s PancreaSure is a blood-based pancreatic cancer diagnostic designed for individuals with inherited or familial risk. The company aims to support

Immunovia AB ( ($SE:IMMNOV) ) has shared an update. Immunovia reported third-quarter 2026 net sales of SEK 843,000, up from SEK 101,000 a year earlier, as PancreaSure sales and royalty

Immunovia AB ( ($SE:IMMNOV) ) has issued an announcement. Pancreatic cancer diagnostics company Immunovia AB will release its interim report for the third quarter of 2026 on November 2 at

An update from Immunovia AB ( ($SE:IMMNOV) ) is now available. Immunovia AB held an extraordinary general meeting on 29 October 2026, where shareholders approved changes to the company’s Articles

Immunovia AB ( ($SE:IMMNOV) ) has provided an announcement. Immunovia AB has set the final terms for a rights issue of up to 1,057,047,973 units, each comprising two shares and

Immunovia AB ( ($SE:IMMNOV) ) has shared an update. Immunovia AB has published peer-reviewed data showing its PancreaSure blood test delivers 77.5% sensitivity and 93.6% specificity in detecting early-stage pancreatic

Immunovia AB ( ($SE:IMMNOV) ) has shared an update. Immunovia plans a rights issue of units, comprising shares and warrants, to initially raise about SEK 63 million, with roughly 80
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 11, 2027Before Open | $8.66M | $-0.00 | $188.58K | 0.01 | -0.27 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.